Of the fungal biomarkers used to diagnose CAPA, BDG and galactomannan (GAL) are the most commonly used, but neither test achieves the required sensitivity, specificity or predictive value to be used to solely diagnose IFI. This evidence concerns the gene GAL and episodic ataxia type 2.